1
|
Wang CG, Li Z, Liu S, Ng CT, Marzuki M, Jeslyn Wong PS, Tan B, Lee A, Hui Lim CF, Bifani P, Fang Z, Ching Wong JC, Setoh YX, Yang YY, Mun CH, Fiona Phua SZ, Lim WQ, Lin L, Cook AR, Tanoto H, Ng LC, Singhal A, Leong YW, Loh XJ. N95 respirator decontamination: a study in reusability. Mater Today Adv 2021; 11:100148. [PMID: 34179746 PMCID: PMC8220445 DOI: 10.1016/j.mtadv.2021.100148] [Citation(s) in RCA: 2] [Impact Index Per Article: 0.7] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Key Words] [Track Full Text] [Subscribe] [Scholar Register] [Received: 01/27/2021] [Revised: 04/20/2021] [Accepted: 04/21/2021] [Indexed: 05/23/2023]
Abstract
The coronavirus disease 2019 (COVID-19) pandemic had caused a severe depletion of the worldwide supply of N95 respirators. The development of methods to effectively decontaminate N95 respirators while maintaining their integrity is crucial for respirator regeneration and reuse. In this study, we systematically evaluated five respirator decontamination methods using vaporized hydrogen peroxide (VHP) or ultraviolet (254 nm wavelength, UVC) radiation. Through testing the bioburden, filtration, fluid resistance, and fit (shape) of the decontaminated respirators, we found that the decontamination methods using BioQuell VHP, custom VHP container, Steris VHP, and Sterrad VHP effectively inactivated Cardiovirus (3-log10 reduction) and bacteria (6-log10 reduction) without compromising the respirator integrity after 2-15 cycles. Hope UVC system was capable of inactivating Cardiovirus (3-log10 reduction) but exhibited relatively poorer bactericidal activity. These methods are capable of decontaminating 10-1000 respirators per batch with varied decontamination times (10-200 min). Our findings show that N95 respirators treated by the previously mentioned decontamination methods are safe and effective for reuse by industry, laboratories, and hospitals.
Collapse
Affiliation(s)
- C-G Wang
- Institute of Materials Research and Engineering (IMRE), Agency for Science, Technology and Research (A∗STAR), 2 Fusionopolis Way, Innovis, No. 08-03, 138634, Singapore
| | - Z Li
- Institute of Materials Research and Engineering (IMRE), Agency for Science, Technology and Research (A∗STAR), 2 Fusionopolis Way, Innovis, No. 08-03, 138634, Singapore
| | - S Liu
- Institute of Materials Research and Engineering (IMRE), Agency for Science, Technology and Research (A∗STAR), 2 Fusionopolis Way, Innovis, No. 08-03, 138634, Singapore
| | - C T Ng
- Environmental Health Institute, National Environment Agency (NEA), 11 Biopolis Way No.06-05/08 Helios Block, 138667, Singapore
| | - M Marzuki
- A∗STAR Infectious Diseases Labs, Agency for Science, Technology and Research (A∗STAR), 8A Biomedical Grove, 138648, Singapore
- Singapore Immunology Network (SIgN), Agency for Science, Technology and Research (A∗STAR), 8A Biomedical Grove, 138648, Singapore
| | - P S Jeslyn Wong
- Environmental Health Institute, National Environment Agency (NEA), 11 Biopolis Way No.06-05/08 Helios Block, 138667, Singapore
| | - B Tan
- A∗STAR Infectious Diseases Labs, Agency for Science, Technology and Research (A∗STAR), 8A Biomedical Grove, 138648, Singapore
- Singapore Immunology Network (SIgN), Agency for Science, Technology and Research (A∗STAR), 8A Biomedical Grove, 138648, Singapore
| | - A Lee
- A∗STAR Infectious Diseases Labs, Agency for Science, Technology and Research (A∗STAR), 8A Biomedical Grove, 138648, Singapore
- Singapore Immunology Network (SIgN), Agency for Science, Technology and Research (A∗STAR), 8A Biomedical Grove, 138648, Singapore
| | - C F Hui Lim
- A∗STAR Infectious Diseases Labs, Agency for Science, Technology and Research (A∗STAR), 8A Biomedical Grove, 138648, Singapore
- Singapore Immunology Network (SIgN), Agency for Science, Technology and Research (A∗STAR), 8A Biomedical Grove, 138648, Singapore
| | - P Bifani
- A∗STAR Infectious Diseases Labs, Agency for Science, Technology and Research (A∗STAR), 8A Biomedical Grove, 138648, Singapore
- Singapore Immunology Network (SIgN), Agency for Science, Technology and Research (A∗STAR), 8A Biomedical Grove, 138648, Singapore
| | - Z Fang
- Environmental Health Institute, National Environment Agency (NEA), 11 Biopolis Way No.06-05/08 Helios Block, 138667, Singapore
| | - J C Ching Wong
- Environmental Health Institute, National Environment Agency (NEA), 11 Biopolis Way No.06-05/08 Helios Block, 138667, Singapore
| | - Y X Setoh
- Environmental Health Institute, National Environment Agency (NEA), 11 Biopolis Way No.06-05/08 Helios Block, 138667, Singapore
| | - Y Y Yang
- Institute of Bioengineering and Bioimaging, Agency for Science, Technology and Research (A∗STAR), 31 Biopolis Way, Nanos, 138669, Singapore
| | - C H Mun
- DSO National Laboratories, 12 Science Park Dr, 118225, Singapore
| | - S Z Fiona Phua
- DSO National Laboratories, 12 Science Park Dr, 118225, Singapore
| | - W Q Lim
- DSO National Laboratories, 12 Science Park Dr, 118225, Singapore
| | - L Lin
- ST Engineering Aerospace Engines Pte Ltd, 501 Airport Rd, 539931, Singapore
| | - A R Cook
- Saw Swee Hock School of Public Health, National University of Singapore and National University Health System, 12 Science Drive 2, 117549, Singapore
| | - H Tanoto
- Institute of Materials Research and Engineering (IMRE), Agency for Science, Technology and Research (A∗STAR), 2 Fusionopolis Way, Innovis, No. 08-03, 138634, Singapore
| | - L-C Ng
- Environmental Health Institute, National Environment Agency (NEA), 11 Biopolis Way No.06-05/08 Helios Block, 138667, Singapore
- School of Biological Sciences, Nanyang Technological University, 60 Nanyang Drive, 637551, Singapore
| | - A Singhal
- A∗STAR Infectious Diseases Labs, Agency for Science, Technology and Research (A∗STAR), 8A Biomedical Grove, 138648, Singapore
- Singapore Immunology Network (SIgN), Agency for Science, Technology and Research (A∗STAR), 8A Biomedical Grove, 138648, Singapore
| | - Y W Leong
- Institute of Materials Research and Engineering (IMRE), Agency for Science, Technology and Research (A∗STAR), 2 Fusionopolis Way, Innovis, No. 08-03, 138634, Singapore
| | - X J Loh
- Institute of Materials Research and Engineering (IMRE), Agency for Science, Technology and Research (A∗STAR), 2 Fusionopolis Way, Innovis, No. 08-03, 138634, Singapore
| |
Collapse
|
2
|
Eisner DR, Hui A, Eppler K, Tegoulia V, Maa YF. Stability Evaluation of Hydrogen Peroxide Uptake Samples from Monoclonal Antibody Drug Product Aseptically Filled in Vapor Phase Hydrogen Peroxide-Sanitized Barrier Systems: A Case Study. PDA J Pharm Sci Technol 2019; 73:285-291. [PMID: 30651338 DOI: 10.5731/pdajpst.2018.009340] [Citation(s) in RCA: 5] [Impact Index Per Article: 1.0] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Key Words] [MESH Headings] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 06/09/2023]
Abstract
During the manufacture of a monoclonal antibody drug product, which was aseptically filled within a vapor phase hydrogen peroxide-sanitized isolator, samples were taken to investigate the hydrogen peroxide uptake behaviors. Surprisingly, the samples had no detectable hydrogen peroxide (most results below the limit of detection). This finding was later attributed to hydrogen peroxide decomposition after the samples were stored frozen at -20°C for two weeks before testing. This case study highlights the criticality of storage conditions for hydrogen peroxide-containing samples and summarizes an investigation on hydrogen peroxide stability in water and in three monoclonal antibody solutions having a wide protein concentration range (30-200 mg/mL). Samples were stored at three temperatures (-70°C, -20°C, or 2-8°C) for up to 28 days to assess the impact of protein concentration and storage temperature on hydrogen peroxide decomposition rates. Hydrogen peroxide degraded slightly more rapidly with increasing protein concentration independent of storage condition. When stored at -20°C, hydrogen peroxide was least stable and degraded faster than when stored at 2-8°C. Hydrogen peroxide was most stable when the samples were stored at -70°C. Overall, this case study brings the hydrogen peroxide stability issue to the attention of process development scientists and engineers and offers a valuable lesson learned during process development.LAY ABSTRACT: The use of vapor phase hydrogen peroxide as a sanitizing agent for isolator and cleanroom decontamination has become common in recent years. Because of the potential impact of residual hydrogen peroxide on biopharmaceutical product quality, hydrogen peroxide uptake behaviors and mechanisms during the manufacturing process within these barriers need to be evaluated and understood. Samples taken from various small-scale and manufacturing-scale hydrogen peroxide uptake studies are often stored frozen before testing. This case study reports an important and interesting finding about hydrogen peroxide stability in samples collected for hydrogen peroxide uptake investigation, and it demonstrates the relationship between hydrogen peroxide stability and storage temperature, storage duration, and monoclonal antibody concentration. The approach and outcome of this study are expected to benefit scientists and engineers who develop biologic product manufacturing processes by providing a better understanding of drug product process challenges and appropriate sample storage.
Collapse
Affiliation(s)
- Devon Roshan Eisner
- Pharmaceutical Processing and Technology Development, Genentech, a Member of the Roche Group, 1 DNA Way South San Francisco, CA 94080; and
| | - Ada Hui
- Late Stage Pharmaceutical Development, Genentech, a Member of the Roche Group, 1 DNA Way, South San Francisco, CA 94080
| | - Kirk Eppler
- Pharmaceutical Processing and Technology Development, Genentech, a Member of the Roche Group, 1 DNA Way South San Francisco, CA 94080; and
| | - Vassia Tegoulia
- Pharmaceutical Processing and Technology Development, Genentech, a Member of the Roche Group, 1 DNA Way South San Francisco, CA 94080; and
| | - Yuh-Fun Maa
- Pharmaceutical Processing and Technology Development, Genentech, a Member of the Roche Group, 1 DNA Way South San Francisco, CA 94080; and
| |
Collapse
|